Proteomic Applications and Considerations: From Research to Patient Care.
Biomarker
Clinical utility
Plasma
Proteomics
Serum
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2023
2023
Historique:
entrez:
13
2
2023
pubmed:
14
2
2023
medline:
16
2
2023
Statut:
ppublish
Résumé
Despite technological advancements in the field of proteomics, the rate at which serum and plasma biomarkers identified using proteomic approaches are translated into clinical use remains extremely low. In this chapter, we describe recent technological advancements and analytical strategies in proteomic methods. We also describe the progress of proteomic blood-based biomarkers to date and discuss what the future of proteomics might entail with the use of multi-omic approaches and implementing machine learning on large proteomic datasets. Lastly, we provide several key considerations for biomarker studies, ranging from sample type to the use of reference samples, in order to achieve progress from bench to bedside, ultimately improving patient diagnosis, disease, and/or therapeutic monitoring and care.
Identifiants
pubmed: 36781786
doi: 10.1007/978-1-0716-2978-9_12
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-192Informations de copyright
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Letunica N, Van Den Helm S, McCafferty C et al (2022) Proteomics in thrombosis and hemostasis. Thromb Haemost 122(7):1076–1084. https://doi.org/10.1055/a-1690-8897
doi: 10.1055/a-1690-8897
Deutsch EW, Omenn GS, Sun Z et al (2021) Advances and utility of the human plasma proteome. J Proteome Res 20:5241–5263
doi: 10.1021/acs.jproteome.1c00657
Yates JR III (2019) Recent technical advances in proteomics. F1000Res 8:351
doi: 10.12688/f1000research.16987.1
Aslam B, Basit M, Nisar MA et al (2017) Proteomics: technologies and their applications. J Chromatogr Sci 55:182–196
doi: 10.1093/chromsci/bmw167
Macklin A, Khan S, Kislinger T (2020) Recent advances in mass spectrometry based clinical proteomics: applications to cancer research. Clin Proteomics 17:17
doi: 10.1186/s12014-020-09283-w
Messner CB, Demichev V, Bloomfield N et al (2021) Ultra-fast proteomics with Scanning SWATH. Nat Biotechnol 39:846–854
doi: 10.1038/s41587-021-00860-4
Blume JE, Manning WC, Troiano G et al (2020) Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona. Nat Commun 11:3662
doi: 10.1038/s41467-020-17033-7
Kwon YW, Jo H-S, Bae S et al (2021) Application of proteomics in cancer: recent trends and approaches for biomarkers discovery. Front Med 8:747333
doi: 10.3389/fmed.2021.747333
Swiatly A, Horala A, Matysiak J et al (2018) Understanding ovarian cancer: iTRAQ-based proteomics for biomarker discovery. Int J Mol Sci 19:E2240
doi: 10.3390/ijms19082240
Moulder R, Bhosale SD, Goodlett DR et al (2018) Analysis of the plasma proteome using iTRAQ and TMT-based isobaric labeling. Mass Spectrom Rev 37:583–606
doi: 10.1002/mas.21550
Zhang Z, Yu J, Wang P et al (2021) iTRAQ-based proteomic profiling reveals protein alterations after traumatic brain injury and supports thyroxine as a potential treatment. Mol Brain 14:25
doi: 10.1186/s13041-021-00739-0
Patel VJ, Thalassinos K, Slade SE et al (2009) A comparison of labeling and label-free mass spectrometry-based proteomics approaches. J Proteome Res 8:3752–3759
doi: 10.1021/pr900080y
Ignjatovic V, Geyer PE, Palaniappan KK et al (2019) Mass spectrometry-based plasma proteomics: considerations from sample collection to achieving translational data. J Proteome Res 18:4085–4097
doi: 10.1021/acs.jproteome.9b00503
Dowell JA, Wright LJ, Armstrong EA et al (2021) Benchmarking quantitative performance in label-free proteomics. ACS Omega 6:2494–2504
doi: 10.1021/acsomega.0c04030
FDA-NIH Biomarker Working Group (2016) BEST (Biomarkers, EndpointS, and other Tools) Resource. Food and Drug Administration (US), Silver Spring
Manzanares J, Sala F, Gutiérrez MSG et al (2021) Biomarkers. In: Reference module in biomedical sciences. Elsevier, London p B9780128204726000000
Bennett MR, Devarajan P (2011) Characteristics of an ideal biomarker of kidney diseases. In: Biomarkers of kidney disease. Elsevier, London, pp 1–24
Amiri-Dashatan N, Koushki M, Abbaszadeh H-A et al (2018) Proteomics applications in health: biomarker and drug discovery and food industry. Iran J Pharm Res 17:1523–1536
Geyer PE, Holdt LM, Teupser D et al (2017) Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol 13:942
doi: 10.15252/msb.20156297
Hu S, Loo JA, Wong DT (2006) Human body fluid proteome analysis. Proteomics 6:6326–6353
doi: 10.1002/pmic.200600284
Omenn GS, States DJ, Adamski M et al (2005) Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5:3226–3245
doi: 10.1002/pmic.200500358
Palviainen M, Saraswat M, Varga Z et al (2020) Extracellular vesicles from human plasma and serum are carriers of extravesicular cargo—implications for biomarker discovery. PLoS One 15:e0236439
doi: 10.1371/journal.pone.0236439
Askeland A, Borup A, Østergaard O et al (2020) Mass-spectrometry based proteome comparison of extracellular vesicle isolation methods: comparison of ME-kit, size-exclusion chromatography, and high-speed centrifugation. Biomedicine 8:246
Clayton A, Boilard E, Buzas EI et al (2019) Considerations towards a roadmap for collection, handling and storage of blood extracellular vesicles. J Extracell Vesicles 8:1647027
doi: 10.1080/20013078.2019.1647027
O’Bryant SE, Mielke MM, Rissman RA et al (2017) Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement 13:45–58
doi: 10.1016/j.jalz.2016.09.014
Shi L, Buckley NJ, Bos I et al (2021) Plasma proteomic biomarkers relating to Alzheimer’s disease: a meta-analysis based on our own studies. Front Aging Neurosci 13:712545
doi: 10.3389/fnagi.2021.712545
Ptolemy AS, Rifai N (2010) What is a biomarker? Research investments and lack of clinical integration necessitate a review of biomarker terminology and validation schema. Scand J Clin Lab Invest 70:6–14
doi: 10.3109/00365513.2010.493354
Paulovich AG, Whiteaker JR, Hoofnagle AN et al (2008) The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl 2:1386–1402
doi: 10.1002/prca.200780174
Mischak H, Allmaier G, Apweiler R et al (2010) Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2:46ps42
doi: 10.1126/scitranslmed.3001249
Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24:971–983
doi: 10.1038/nbt1235
Zhang Z, Bast RC, Yu Y et al (2004) Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64:5882–5890
doi: 10.1158/0008-5472.CAN-04-0746
Rai AJ, Zhang Z, Rosenzweig J et al (2002) Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 126:1518–1526
doi: 10.5858/2002-126-1518-PATTMD
Zhang Z, Chan DW (2010) The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomark Prev 19:2995–2999
doi: 10.1158/1055-9965.EPI-10-0580
Nolen BM, Lokshin AE (2013) Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Mol Diagn Ther 17:139–146
doi: 10.1007/s40291-013-0027-6
Gupta MK, Polisetty RV, Sharma R et al (2019) Altered transcriptional regulatory proteins in glioblastoma and YBX1 as a potential regulator of tumor invasion. Sci Rep 9:10986
doi: 10.1038/s41598-019-47360-9
Bai Y, Zhan Y, Yu B et al (2018) A novel tumor-suppressor, CDH18, inhibits glioma cell invasiveness via UQCRC2 and correlates with the prognosis of glioma patients. Cell Physiol Biochem 48:1755–1770
doi: 10.1159/000492317
O’Connell GC, Walsh KB, Burrage E et al (2018) High-throughput profiling of the circulating proteome suggests sexually dimorphic corticosteroid signaling following ischemic stroke. Physiol Genomics 50:876–883
doi: 10.1152/physiolgenomics.00058.2018
Bruzelius M, Iglesias MJ, Hong M-G et al (2016) PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study. Blood 128:e59–e66
doi: 10.1182/blood-2016-05-711846
Jensen SB, Hindberg K, Solomon T et al (2018) Discovery of novel plasma biomarkers for future incident venous thromboembolism by untargeted synchronous precursor selection mass spectrometry proteomics. J Thromb Haemost 16:1763–1774
doi: 10.1111/jth.14220
Hier DB, Obafemi-Ajayi T, Thimgan MS et al (2021) Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues. Biomark Res 9:70
doi: 10.1186/s40364-021-00325-5
FDA. FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults, https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-first-blood-test-aid-evaluation-concussion-adults
Wang KKW, Kobeissy FH, Shakkour Z et al (2021) Thorough overview of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein as tandem biomarkers recently cleared by US Food and Drug Administration for the evaluation of intracranial injuries among patients with traumatic brain injury. Acute Med Surg 8:e622
doi: 10.1002/ams2.622
Parkin GM, Clarke C, Takagi M et al (2019) Plasma tumor necrosis factor alpha is a predictor of persisting symptoms post-concussion in children. J Neurotrauma 36:1768–1775
doi: 10.1089/neu.2018.6042
Hanash S, Celis JE (2002) The human proteome organization. Mol Cell Proteomics 1:413–414
doi: 10.1074/mcp.R200002-MCP200
Meyer HE, Klose J, Hamacher M (2003) HBPP and the pursuit of standardisation. Lancet Neurol 2:657–658
doi: 10.1016/S1474-4422(03)00580-5
Deutsch EW, Lane L, Overall CM et al (2019) Human proteome project mass spectrometry data interpretation guidelines 3.0. J Proteome Res 18:4108–4116
doi: 10.1021/acs.jproteome.9b00542
Weissler EH, Naumann T, Andersson T et al (2021) The role of machine learning in clinical research: transforming the future of evidence generation. Trials 22:537
doi: 10.1186/s13063-021-05489-x
May M (2021) Eight ways machine learning is assisting medicine. Nat Med 27:2–3
doi: 10.1038/s41591-020-01197-2
Gogas P, Papadimitriou T (2021) Machine learning in economics and finance. Comput Econ 57:1–4
doi: 10.1007/s10614-021-10094-w
Xu LL, Young A, Zhou A et al (2020) Machine learning in mass spectrometric analysis of DIA data. Proteomics 20:1900352
doi: 10.1002/pmic.201900352
Bouwmeester R, Gabriels R, Van Den Bossche T et al (2020) The age of data-driven proteomics: how machine learning enables novel workflows. Proteomics 20:1900351
doi: 10.1002/pmic.201900351
Meyer JG (2021) Deep learning neural network tools for proteomics. Cell Rep Methods 1:100003
doi: 10.1016/j.crmeth.2021.100003
Wen B, Zeng W, Liao Y et al (2020) Deep learning in proteomics. Proteomics 20:1900335
doi: 10.1002/pmic.201900335
Nesvizhskii AI (2014) Proteogenomics: concepts, applications and computational strategies. Nat Methods 11:1114–1125
doi: 10.1038/nmeth.3144
Mani DR, Krug K, Zhang B et al (2022) Cancer proteogenomics: current impact and future prospects. Nat Rev Cancer 22:298–313
doi: 10.1038/s41568-022-00446-5
Bjelosevic S, Pascovici D, Ping H et al (2017) Quantitative age-specific variability of plasma proteins in healthy neonates, children and adults. Mol Cell Proteomics 16:924–935
doi: 10.1074/mcp.M116.066720